193 related articles for article (PubMed ID: 27612176)
1. Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.
Toft-Petersen M; Nederby L; Kjeldsen E; Kerndrup GB; Brown GD; Hokland P; Stidsholt Roug A
Br J Haematol; 2016 Nov; 175(3):393-401. PubMed ID: 27612176
[TBL] [Abstract][Full Text] [Related]
2. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
Bill M; Aggerholm A; Kjeldsen E; Roug AS; Hokland P; Nederby L
Br J Haematol; 2019 Mar; 184(5):769-781. PubMed ID: 30520015
[TBL] [Abstract][Full Text] [Related]
3. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.
Bill M; B van Kooten Niekerk P; S Woll P; Laine Herborg L; Stidsholt Roug A; Hokland P; Nederby L
J Cell Mol Med; 2018 Apr; 22(4):2311-2318. PubMed ID: 29411522
[TBL] [Abstract][Full Text] [Related]
4. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
[TBL] [Abstract][Full Text] [Related]
5. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
Petersen MA; Rosenberg CA; Brøndum RF; Aggerholm A; Kjeldsen E; Rahbek O; Ludvigsen M; Hasle H; Roug AS; Bill M
Br J Haematol; 2022 May; 197(4):452-466. PubMed ID: 35298835
[TBL] [Abstract][Full Text] [Related]
7. The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia.
Toft-Petersen M; Stidsholt Roug A; Plesner T; Ebbesen L; Brown GD; Nederby L
Cytometry B Clin Cytom; 2018 May; 94(3):520-526. PubMed ID: 28718199
[TBL] [Abstract][Full Text] [Related]
8. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
Morsink LM; Walter RB; Ossenkoppele GJ
Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
[TBL] [Abstract][Full Text] [Related]
10. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
Mohd Amin A; Panneerselvan N; Md Noor S; Mohtaruddin N; Sathar J; Norbaya WS; Osman R; Kee LH; Mohd Yaakub WH; Cheong SK; Abdullah M
Malays J Pathol; 2023 Apr; 45(1):65-76. PubMed ID: 37119247
[TBL] [Abstract][Full Text] [Related]
11. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
[TBL] [Abstract][Full Text] [Related]
12. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
13. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
van Rhenen A; van Dongen GA; Kelder A; Rombouts EJ; Feller N; Moshaver B; Stigter-van Walsum M; Zweegman S; Ossenkoppele GJ; Jan Schuurhuis G
Blood; 2007 Oct; 110(7):2659-66. PubMed ID: 17609428
[TBL] [Abstract][Full Text] [Related]
14. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
Li Q; Liang C; Xu X; Zhang C; Cao W; Wang M; Jiang Z; Xing H; Yu J
Leuk Lymphoma; 2022 Sep; 63(9):2136-2148. PubMed ID: 35481814
[TBL] [Abstract][Full Text] [Related]
15. Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML.
Li LJ; Tao JL; Fu R; Wang HQ; Jiang HJ; Yue LZ; Zhang W; Liu H; Shao ZH
Int J Hematol; 2014 Jul; 100(1):60-9. PubMed ID: 24846193
[TBL] [Abstract][Full Text] [Related]
16. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
[TBL] [Abstract][Full Text] [Related]
19. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
20. Antigen Expression Varies Significantly between Molecular Subgroups of Acute Myeloid Leukemia Patients: Clinical Applicability Is Hampered by Establishment of Relevant Cutoffs.
Herborg LL; Nederby L; Brøndum RF; Hansen M; Hokland P; Roug AS
Acta Haematol; 2021; 144(3):275-284. PubMed ID: 33271547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
